Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant FOLFOX4 for HCC with High FR+CTC
NCT04521491Unknown
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of oxaliplatin, fluorouracil and folinic acid in hepatocellular carcinoma (HCC), sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoint: Recurrence Free Survival at 2 years. Status: unknown.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04521491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521491.